Get the Daily Brief
Latest Biotech News
In vivo CAR-T deal transforms Lilly’s pipeline
Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion, adding an in vivo CAR-T platform aimed at generating anti-BCMA CAR T cells directly inside patients. The deal includes a...
Obesity pipeline gets a $625m IPO as Phase III advances
Kailera Therapeutics priced its IPO at $16 per share, aiming to raise about $625 million in gross proceeds to advance obesity programs and operations. The company plans to trade on Nasdaq under...
Phase III cash infusion to push chronic cough drug into pivotal testing
Trevi Therapeutics closed a $173 million public offering to move its chronic cough program, Haduvio, into Phase III. The company sold 13.34 million shares at $13.00 each, with underwriters...
Cutting-edge genetic medicine startup targets durable expression without genome edits
Flagship Pioneering launched Serif Biomedicines with a $50 million debut to pursue what it describes as “modified DNA” medicines designed to durably express therapeutic proteins without altering a...
R&D toolchain: proteomics measurement gets embedded into clinical workflows
Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Nomic Omni 1000 immunoassay platform into Broad Clinical Labs’ omics offerings. The collaboration is intended to connect...
Sequencing for MRD: Foundation Medicine buys SAGA Diagnostics
Roche said Foundation Medicine will acquire SAGA Diagnostics in a deal valued at up to $595 million, expanding its molecular residual disease (MRD) portfolio. Foundation will integrate SAGA’s...
Genome-wide CRISPR maps host genes that control HIV infection
Gladstone Institutes and UCSF reported a genome-wide CRISPR map of human genes that either promote or restrict HIV infection in primary CD4+ T cells. Published in Cell, the study addresses a...
AACR diagnostic AI: methylation model identifies cancers of unknown primary
Researchers from Kindai University presented an AI model at AACR 2026 that predicts the origin of cancers of unknown primary (CUP) by analyzing CpG DNA methylation patterns. The team reported that...
Clinical supply and payments: automation targets manual trial site invoicing
Ledger Run upgraded its ClinRun platform to streamline clinical trial payment workflows by automating processing of site invoiceables—costs not accounted for in study budgets. The company said its...
Clinical pipeline: GSK ADC posts Phase I response signals in ovarian and endometrial cancers
GSK reported positive early results from its Phase I BEHOLD-1 trial of mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting B7-H4, in platinum-resistant ovarian cancer and recurrent...
In vivo CAR T expansion via M&A
Eli Lilly agreed to buy Kelonia Therapeutics in a deal worth up to $7 billion, adding an in vivo CAR T platform aimed at generating anti-BCMA T cells directly inside patients. Lilly will pay $3.25...
Early interception strategy in smoldering myeloma with CAR T
Dana-Farber Cancer Institute investigators presented Phase 2 CAR-PRISM data using CAR T-cell therapy in high-risk smoldering multiple myeloma, a precursor stage aimed at preventing progression. In...
Precision host-factor genomics in primary CD4 T cells for HIV
Gladstone Institutes and UCSF reported a genome-wide CRISPR map of human genes that promote or restrict HIV infection in primary CD4+ T cells. Published in Cell, the work provides a host–virus...
Oncology immunotherapy signal in NEOPRISM-CRC bowel cancer
UCL and UCLH reported follow-up results from the NEOPRISM-CRC trial testing a short course of immunotherapy before surgery for a subset of bowel cancer patients. The update highlighted zero...
Proteomics platform partnership for precision oncology workflows
Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Nomic Omni 1000 immunoassay platform into BCL’s omics offerings. The collaboration is intended to combine broad protein...
Spatial biology platform launch pressures competitors
10x Genomics launched Atera at AACR, positioning the in situ spatial biology platform for whole-transcriptome analysis at high throughput. The company said Atera can image multiple slides per run,...
Clinical pipeline update in alopecia areata with IL-2 biology
Nektar reported Phase II extension results for rezpegaldesleukin (rezpeg) in severe alopecia areata, describing additional hair regrowth in patients continuing treatment. The update focused on...
Regulatory-grade evidence for MRD sequencing in TRACERx
Ultima Genomics reported TRACERx trial data supporting a whole-genome ctDNA approach using duplex sequencing without bespoke tumor-informed assays. At AACR, Jonathan Wan of UCL and the Francis...
Therapeutic strategy in ulcerative colitis via JAK1–NLRP3 pathway
Researchers reported in Nature Communications that JAK1 inhibitors reduce ulcerative colitis activity through suppression of the NLRP3–IL-1β signaling axis. The mechanistic work links a widely...
Lilly in vivo genetic medicines acquisition strategy expands
Industry reporting detailed how Lilly’s Kelonia acquisition fits a broader “in vivo” genetic medicines strategy, building on prior deals to expand the company’s cell therapy and genetic medicine...